CIBC Private Wealth Group LLC Sells 139,870 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

CIBC Private Wealth Group LLC lessened its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 91.1% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 13,597 shares of the medical research company's stock after selling 139,870 shares during the quarter. CIBC Private Wealth Group LLC's holdings in Charles River Laboratories International were worth $2,555,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Wellington Management Group LLP lifted its holdings in Charles River Laboratories International by 135,927.9% in the third quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company's stock worth $736,819,000 after purchasing an additional 3,738,018 shares during the period. Norges Bank acquired a new stake in shares of Charles River Laboratories International in the 4th quarter worth approximately $98,886,000. Raymond James Financial Inc. bought a new position in shares of Charles River Laboratories International in the fourth quarter valued at approximately $42,776,000. Cooke & Bieler LP increased its stake in shares of Charles River Laboratories International by 42.1% during the fourth quarter. Cooke & Bieler LP now owns 426,767 shares of the medical research company's stock valued at $78,781,000 after acquiring an additional 126,372 shares during the period. Finally, JPMorgan Chase & Co. raised its holdings in Charles River Laboratories International by 21.6% during the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company's stock worth $95,086,000 after purchasing an additional 85,759 shares in the last quarter. Institutional investors own 98.91% of the company's stock.

Remove Ads

Charles River Laboratories International Stock Down 2.1 %

NYSE:CRL traded down $2.93 during trading hours on Monday, hitting $133.97. 1,984,855 shares of the company's stock traded hands, compared to its average volume of 776,316. The stock's fifty day moving average price is $161.85 and its two-hundred day moving average price is $180.06. The firm has a market cap of $6.85 billion, a P/E ratio of 893.11, a P/E/G ratio of 4.54 and a beta of 1.45. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. Charles River Laboratories International, Inc. has a twelve month low of $128.03 and a twelve month high of $258.56.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating analysts' consensus estimates of $2.50 by $0.16. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm's quarterly revenue was down 1.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.46 EPS. On average, research analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Charles River Laboratories International news, COO Birgit Girshick acquired 1,514 shares of the business's stock in a transaction that occurred on Thursday, February 20th. The shares were purchased at an average price of $164.63 per share, with a total value of $249,249.82. Following the completion of the transaction, the chief operating officer now owns 55,058 shares in the company, valued at $9,064,198.54. The trade was a 2.83 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Joseph W. Laplume sold 4,400 shares of the business's stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the sale, the executive vice president now directly owns 20,013 shares of the company's stock, valued at $3,252,112.50. This represents a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.30% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Redburn Atlantic upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price target on the stock in a research report on Monday, March 3rd. Morgan Stanley dropped their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 5th. The Goldman Sachs Group downgraded shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and cut their price target for the company from $190.00 to $170.00 in a report on Friday, March 21st. Citigroup raised shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and lifted their price objective for the stock from $155.00 to $175.00 in a research note on Tuesday, March 4th. Finally, William Blair lowered shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research note on Wednesday, January 22nd. One equities research analyst has rated the stock with a sell rating and sixteen have given a hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $189.77.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).